^
Association details:
| Biomarker: | ALK fusion + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations
Published date:
08/02/2023
Excerpt:
ALK fusions were detected in the ctDNA of 62 patients in the lorlatinib arm and 64 patients in the crizotinib arm….In the lorlatinib arm, PFS was lower in patients who had a co-occurring TP53 mutation.
DOI:
https://doi.org/10.1016/j.jtho.2023.07.023
